{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:48:09Z","timestamp":1787161689278,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      While PD-L1 expression heterogeneity limits the predictive value of localized biopsies, molecular imaging offers a dynamic alternative. We developed [\n                      <jats:sup>18<\/jats:sup>\n                      F]AlF-NOTA-PCP2, a hydrophilic PD-L1\u2013targeted peptide tracer, and first evaluated its clinical utility in head and neck (HNC) cancer through a head-to-head comparison with [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Preclinical validation included competitive binding assays and micro-PET\/CT in PD-L1\u2013positive HNC xenografts. A prospective trial (NCT04304066) enrolled 24 HNC patients for [\n                      <jats:sup>18<\/jats:sup>\n                      F]AlF-NOTA-PCP2 PET\/CT, with paired [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG scans in 17 patients. PD-L1 expression was quantified via 22C3 immunohistochemistry (IHC). Safety, biodistribution, and tracer correlations were analyzed, with dynamic PD-L1 changes monitored in 5 pembrolizumab-treated patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]AlF-NOTA-PCP2 exhibited high PD-L1 affinity (IC\n                      <jats:sub>50<\/jats:sub>\n                      = 24.7\u00a0nM) and selectively targeted PD-L1\u2013positive tumors in preclinical models. In 24 HNC patients, tracer uptake strongly correlated with PD-L1 TPS (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sub>s<\/jats:sub>\n                      = 0.890,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Favorable biodistribution and minimal off-target uptake were observed, with the highest accumulation in the spleen and PD-L1\u2013positive lesions. Head-to-head analysis (58 lesions, n = 17) revealed limited concordance between [\n                      <jats:sup>18<\/jats:sup>\n                      F]AlF-NOTA-PCP2 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG SUVmax (\n                      <jats:italic toggle=\"yes\">rs<\/jats:italic>\n                      = 0.323,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.042). Tracer uptake varied by HPV status (HPV+ vs. HPV\u2212: 5.93 \u00b1 2.61 vs. 2.25 \u00b1 0.57,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007) and anatomic site. Dynamic monitoring in immunotherapy responders showed early [\n                      <jats:sup>18<\/jats:sup>\n                      F]AlF-NOTA-PCP2 uptake reduction (\u0394SUVmax = \u221237.7%) preceding metabolic changes on FDG, reflecting PD-L1 downregulation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]AlF-NOTA-PCP2 PET\/CT provides a superior, noninvasive approach for evaluating PD-L1 expression in HNC. Its high specificity for PD-L1 and favorable biodistribution position it as a promising tool for monitoring immunotherapy responses and informing treatment decisions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006151","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:00:22Z","timestamp":1765328422000},"page":"2-12","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["[18F]AlF-NOTA-PCP2 PET\/CT to Assess PD-L1 Status in Head and Neck Cancer"],"prefix":"10.1097","volume":"51","author":[{"given":"Yong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"},{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of PET\/CT Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging, Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewen","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of PET\/CT Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging, Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-sheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-286X","authenticated-orcid":false,"given":"Man","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"R1-20251210","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20251210","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s10147-024-02632-x","article-title":"First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE\u2011048","volume":"29","author":"Oridate","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"R3-20251210","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20251210","doi-asserted-by":"crossref","first-page":"101202","DOI":"10.1016\/j.drup.2025.101202","article-title":"Peptide-based PET\/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma","volume":"79","author":"Wang","year":"2025","journal-title":"Drug Resist Updat"},{"key":"R5-20251210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/neuonc\/noae190","article-title":"Imaging PD-L1 in the brain\u2014journey from the lab to the clinic","volume":"27","author":"Dar","year":"2025","journal-title":"Neuro Oncol"},{"key":"R6-20251210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41416-023-02297-9","article-title":"Relationship between the expression of PD-L1 and (18)F-FDG uptake in pancreatic ductal adenocarcinoma","volume":"129","author":"Li","year":"2023","journal-title":"Br J Cancer"},{"key":"R7-20251210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/bjr\/tqaf034","article-title":"Using 18F-FDG PET\/CT to predict PD-L1 expression in NSCLC via metabolic tumor heterogeneity","volume":"98","author":"Chang","year":"2025","journal-title":"Br J Radiol"},{"key":"R8-20251210","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1007\/s00259-023-06251-y","article-title":"Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma","volume":"50","author":"Zhou","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20251210","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1007\/s00259-025-07201-6","article-title":"Relationship between PD-L1 expression and [(18)F]FAPI versus [(18)F]FDG uptake on PET\/CT in lung cancer","volume":"52","author":"Qin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20251210","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.lungcan.2019.06.009","article-title":"Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer","volume":"134","author":"Kasahara","year":"2019","journal-title":"Lung Cancer"},{"key":"R11-20251210","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"R12-20251210","doi-asserted-by":"crossref","first-page":"e008794","DOI":"10.1136\/jitc-2024-008794","article-title":"Preclinical development of novel PD-L1 tracers and first-in-human study of [(68)Ga]Ga-NOTA-RW102 in patients with lung cancers","volume":"12","author":"Zhang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R13-20251210","doi-asserted-by":"crossref","first-page":"e2107982118","DOI":"10.1073\/pnas.2107982118","article-title":"Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics","volume":"118","author":"Kumar","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"R14-20251210","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4103\/jcrt.jcrt_88_23","article-title":"An overview of current advances of PD-L1 targeting immuno-imaging in cancers","volume":"19","author":"Chen","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R15-20251210","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00259-023-06480-1","article-title":"Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy","volume":"51","author":"Zhu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20251210","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI122216","article-title":"Peptide-based PET quantifies target engagement of PD-L1 therapeutics","volume":"129","author":"Kumar","year":"2019","journal-title":"J Clin Invest"},{"key":"R17-20251210","doi-asserted-by":"crossref","first-page":"1536012119852189","DOI":"10.1177\/1536012119852189","article-title":"Development of [(18)F]FPy-WL12 as a PD-L1 specific PET imaging peptide","volume":"18","author":"Lesniak","year":"2019","journal-title":"Mol Imaging"},{"key":"R18-20251210","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J Nucl Med"},{"key":"R19-20251210","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s00259-024-06743-5","article-title":"[(18)F]AlF-NOTA-PCP2: a novel PET\/CT tracer for enhanced PD-L1 heterogeneity imaging and comparative analysis with [(18)F]AlF-NOTA-WL12 in glioblastoma xenografts","volume":"51","author":"Wang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20251210","doi-asserted-by":"crossref","first-page":"101082","DOI":"10.1016\/j.jpha.2024.101082","article-title":"Peptide-based immuno-PET\/CT monitoring of dynamic PD-L1 expression during glioblastoma radiotherapy","volume":"15","author":"Wang","year":"2025","journal-title":"J Pharma Anal"},{"key":"R21-20251210","doi-asserted-by":"crossref","first-page":"141080","DOI":"10.1016\/j.cej.2022.141080","article-title":"Custom-built automated radiosynthesis platform for Al [18F] F radiochemistry and its application for clinical production","volume":"456","author":"Fu","year":"2023","journal-title":"Chem Eng J"},{"key":"R22-20251210","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"R23-20251210","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41388-023-02927-9","article-title":"HPV-associated oropharyngeal cancer: in search of surrogate biomarkers for early lesions","volume":"43","author":"Lim","year":"2024","journal-title":"Oncogene"},{"key":"R24-20251210","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1017\/S0022215116000505","article-title":"Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines","volume":"130","author":"Mehanna","year":"2016","journal-title":"J Laryngol Otol"},{"key":"R25-20251210","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1159\/000515441","article-title":"Spatial intratumoral heterogeneity expression of PD-L1 antigen in head and neck squamous cell carcinoma","volume":"99","author":"Hirshoren","year":"2021","journal-title":"Oncology"},{"key":"R26-20251210","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"key":"R27-20251210","doi-asserted-by":"crossref","first-page":"e007670","DOI":"10.1136\/jitc-2023-007670","article-title":"M1 macrophages induce PD-L1(hi) cell-led collective invasion in HPV-positive head and neck squamous cell carcinoma via TNF-alpha\/CDK4\/UPS14","volume":"11","author":"Wu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R28-20251210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/a-1816-6950","article-title":"Standardized 18F-FDG PET\/CT radiomic features provide information on PD-L1 expression status in treatment-naive patients with non-small cell lung cancer","volume":"61","author":"Zhang","year":"2022","journal-title":"Nuklearmedizin"},{"key":"R29-20251210","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12149-020-01571-7","article-title":"Association between PD-L1 expression and (18)F-FDG uptake in ovarian cancer","volume":"35","author":"Choi","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R30-20251210","doi-asserted-by":"crossref","first-page":"12270","DOI":"10.18632\/aging.102567","article-title":"Relationship between PD-L1 expression and (18)F-FDG uptake in gastric cancer","volume":"11","author":"Chen","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"R31-20251210","doi-asserted-by":"crossref","first-page":"896494","DOI":"10.3389\/fmed.2022.896494","article-title":"Metabolic parameters on baseline (18)F-FDG PET\/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma","volume":"9","author":"Kwon","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R32-20251210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41598-017-18489-2","article-title":"Associations of tumor PD-1 ligands, immunohistochemical studies, and textural features in (18)F-FDG PET in squamous cell carcinoma of the head and neck","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"R33-20251210","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41416-020-0820-z","article-title":"Diagnostic value of (18)F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8(+)tumour-infiltrating lymphocytes in oral squamous cell carcinoma","volume":"122","author":"Togo","year":"2020","journal-title":"Br J Cancer"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:00:41Z","timestamp":1765371641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006151"}},"subtitle":["Head-to-Head Comparison With [18F]FDG PET\/CT"],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006151","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"2025-04-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}